Xn:Harmful;
71-41-0Relevant articles and documents
Erschow,Sepalowa-Mikhailowa
, (1944)
-
Kenyon et al.
, p. 2394 (1950)
-
Ruthenium (II) complexes with C2- and C1-symmetric bis-(+)-camphopyrazole ligands and their evaluation in catalytic transfer hydrogenation of aldehydes
Agrifoglio, Giuseppe,Blanco, Christian O.,Dorta, Romano,Herrera, Alberto,Landaeta, Vanessa R.,Llovera, Ligia,Pastrán, Jesús,Venuti, Doménico
supporting information, (2021/05/10)
Ruthenium (II) piano-stool complexes with bis-(+)-camphopyrazole ligands of C2 and C1 symmetry were prepared in good yields (66–98%). New C2-C1 ligands and complexes were characterized by multinuclear NMR spectroscopy, FT-IR and elemental analysis. The catalytic performance of the Ru(II)-bis-(+)-camphopyrazole complexes in the transfer hydrogenation of benzaldehyde and valeraldehyde using isopropanol/potassium carbonate and formic acid/triethylamine mixtures as hydrogen donors, was evaluated, resulting in moderate yields (>54%) for the reduction to the desired primary alcohols. The system with isopropanol as hydrogen source proved to be more selective than the analogous system using the azeotropic formic acid/triethylamine mixture, allowing benzyl alcohol to be obtained in quantitative yield (>99%) for a particular catalyst precursor. Furthermore, complexes with C2 symmetry ligands showed higher yields than those with C1 symmetry ligands in all of the evaluated systems.
Discovery of Anti-TNBC Agents Targeting PTP1B: Total Synthesis, Structure-Activity Relationship, in Vitro and in Vivo Investigations of Jamunones
Hu, Caijuan,Li, Guoxun,Mu, Yu,Wu, Wenxi,Cao, Bixuan,Wang, Zixuan,Yu, Hainan,Guan, Peipei,Han, Li,Li, Liya,Huang, Xueshi
supporting information, p. 6008 - 6020 (2021/05/06)
Twenty-three natural jamunone analogues along with a series of jamunone-based derivatives were synthesized and evaluated for their inhibitory effects against breast cancer (BC) MDA-MB-231 and MCF-7 cells. The preliminary structure-activity relationship revealed that the length of aliphatic side chain and free phenolic hydroxyl group at the scaffold played a vital role in anti-BC activities and the methyl group on chromanone affected the selectivity of molecules against MDA-MB-231 and MCF-7 cells. Among them, jamunone M (JM) was screened as the most effective anti-triple-negative breast cancer (anti-TNBC) candidate with a high selectivity against BC cells over normal human cells. Mechanistic investigations indicated that JM could induce mitochondria-mediated apoptosis and cause G0/G1 phase arrest in BC cells. Furthermore, JM significantly restrained tumor growth in MDA-MB-231 xenograft mice without apparent toxicity. Interestingly, JM could downregulate phosphatidylinositide 3-kinase (PI3K)/Akt pathway by suppressing protein-tyrosine phosphatase 1B (PTP1B) expression. These findings revealed the potential of JM as an appealing therapeutic drug candidate for TNBC.
